Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-A002 in healthy Dengue-naive adults
NCT03831503Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Feb 2019
- Primary completion
- Oct 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of INO-A002 in Dengue fever (DENV), sponsored by University of Pennsylvania. Started Feb 2019; status: completed.
02
Drugs
INO-A002
03
Conditions
Dengue fever (DENV)
Beyond the preview
Go deeper on NCT03831503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831503.